NK9 trading today higher at 8.1, an increase of 0% from yesterday's close, completing a monthly decrease of -4.7059% or -0.4. Over the past 12 months, NK9 stock lost -21.3592%.
NK9 is not paying dividends to its shareholders.
The last earnings report, released on Feb 26, 2026, missed the consensus estimates by -0.0135%. On average, the company has fell short of earnings expectations by -0.0785%, based on the last three reports.
Neuren Pharmaceuticals Limited has completed 3 stock splits, with the recent split occurring on Nov 21, 2017.
The company's stock is traded on 5 different exchanges and in various currencies, with the primary listing on ASX (AUD).